Your session is about to expire
← Back to Search
Nelipepimut-S + GM-CSF Vaccine for Breast Cancer
Study Summary
This trial is studying two possible treatments for breast cancer. One is a vaccine made from peptide or antigen mixed with tumor proteins. The other is a white blood cell booster called sargramostim. Researchers want to see if either of these treatments is more effective than no treatment at all.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 43 Patients • NCT02636582Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Nelipepimut-S Plus GM-CSF Vaccine for therapeutic use?
"Given the Phase 2 status of Nelipepimut-S Plus GM-CSF Vaccine, there is some evidence that it is safe but not yet any proof of efficacy. As such, our team at Power has given this vaccine a safety rating of 2."
Can you elucidate the number of Canadian locations in which this clinical trial is being conducted?
"At present, 4 clinical sites are running this trial. These locations are in New york, Philadelphia and Boston as well as several other cities. To minimize the burden of enrolment on patients, it is ideal to choose a site near you for participation."
Is the Nelipepimut-S Plus GM-CSF Vaccine being tested in additional clinical trials?
"Nelipepimut-S Plus GM-CSF Vaccine was first trialed in 2001 at the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. A total of 719 trials have been finished and 43 are still ongoing, primarily situated around New york City."
What is the capacity of participants accepted into this research project?
"This trial is not open for recruitment at this time. It was first listed on June 14th, 2016 and the information has recently been updated on June 30th 2021. If you are looking to join other clinical studies there are 133 active trials available involving carcinoma mammary ductal and 43 utilizing Nelipepimut-S Plus GM-CSF Vaccine that require participants."
Is it possible to enter this experiment at the present time?
"Evidently, the clinical trial listed on clinicaltrials.gov is not looking for new participants at this time; it was initially posted on June 14th 2016 and last updated in June 2021. Nevertheless, there are 176 other ongoing medical studies that welcome volunteers."
Share this study with friends
Copy Link
Messenger